The Relationship of Albumin-Bilirubin Grade with Right and Left Colon in Patients with Colon Cancer Treated with Regorafenib
Received Date : 16 Feb 2022
Accepted Date : 19 Jun 2022
Available Online : 04 Jul 2022
Doi: 10.37047/jos.2022-89000 - Article's Language: EN
J Oncol Sci. 2022;8(2):76-86
This is an open access article under the CC BY-NC-ND license
Objective: The purpose of this study is to evaluate the association between albumin-bilirubin (ALBI) grade and right and left colon in colon cancer (CC) patients with liver metastases who received regorafenib treatment. Material and Methods: This retrospective study included 126 patients treated with regorafenib and was divided into normal-ALBI (ALBI Grade 1) and high-ALBI groups (ALBI Grades 2 and 3). The optimal cut-off values of neutrophil-lymphocyte ratio and prognostic nutritional index (PNI), evaluated by receiver operating characteristic curve analysis, were 4.41 and 40.85, respectively. The associations between parameters with survival were analyzed using Kaplan- Meier curves and compared by the log-rank test. Cox proportional hazards regression analyzes were used to evaluate the prognostic significance of the parameters for progression-free survival (PFS) and overall survival (OS). Results: The ALBI group for OS (p=0.043) in the right CC (RCC) and the number of metastatic organs for PFS (p=0.048) were found to be independent prognostic variables. The overall response rate (ORR) was significantly higher in the group with low ALBI for RCC. In RCC, side adverse effects (AE) were higher in the group with high ALBI than in the normal group (p=0.028). The number of metastatic organs in left CC (LCC) (p=0.008, p<0.001, p=0.042) was found to be independent prognostic for both PFS and OS. Both ORR and disease control rate were significantly higher in the LCC group with high PNI. Conclusion: In RCC cases with liver metastases treated with regorafenib, the ALBI group was significantly associated with prognosis, survival, response rates, and AE. ALBI grade should be considered in RCC patients receiving regorafenib therapy.
  1. Loree JM, Kopetz S. Recent developments in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2017;9(8):551-564. [Crossref]  [PubMed]  [PMC] 
  2. Moriwaki T, Fukuoka S, Taniguchi H, et al. Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): A Japanese society for cancer of the colon and rectum multicenter observational study. Oncologist. 2018;23(1):7-15. [Crossref]  [PubMed]  [PMC] 
  3. Ogasawara S, Chiba T, Ooka Y, et al. Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015;33(6):1257-1262. [Crossref]  [PubMed] 
  4. Abdel-Rahman O. Prognostic value of baseline ALBI score among patients with colorectal liver metastases: a pooled analysis of two randomized trials. Clin Colorectal Cancer. 2019;18(1):e61-e68. [Crossref]  [PubMed] 
  5. Grothey A, Van Cutsem E, Sobrero A, et al; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-312. [Crossref]  [PubMed] 
  6. Watanabe D, Fujii H, Yamada Y, et al. Association of albumin-bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib. Int J Clin Oncol. 2021;26(7):1257-1263. [Crossref]  [PubMed] 
  7. Kim HD, Bang Y, Lee MA, et al. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. Liver Int. 2020;40(10):2544-2552. [Crossref]  [PubMed] 
  8. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H; Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53(1):57-64. [Crossref]  [PubMed] 
  9. Yahagi M, Okabayashi K, Hasegawa H, Tsuruta M, Kitagawa Y. The worse prognosis of right-sided compared with left-sided colon cancers: a systematic review and meta-analysis. J Gastrointest Surg. 2016;20(3):648-655. [Crossref]  [PubMed] 
  10. Weiss JM, Pfau PR, O'Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data. J Clin Oncol. 2011;29(33):4401-4409. [Crossref]  [PubMed]  [PMC] 
  11. Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):50. [Crossref]  [PubMed]  [PMC] 
  12. Cho YA, Lee J, Oh JH, et al. Inflammatory dietary pattern, IL-17F genetic variant, and the risk of colorectal cancer. Nutrients. 2018;10(6):724. [Crossref]  [PubMed]  [PMC] 
  13. Guo G, Chen X, He W, et al. Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data. PLoS One. 2018;13(12):e0208547. [Crossref]  [PubMed]  [PMC] 
  14. Ucar G, Ergun Y, Acikgoz Y, Uncu D. The prognostic value of the prognostic nutritional index in patients with metastatic colorectal cancer. Asia Pac J Clin Oncol. 2020;16(5):e179-e184. [Crossref]  [PubMed] 
  15. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-558. [Crossref]  [PubMed]  [PMC] 
  16. Yang SY, Cho MS, Kim NK. Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype. Expert Rev Anticancer Ther. 2018;18(4):351-358. [Crossref]  [PubMed] 
  17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. [Crossref]  [PubMed] 
  18. U.S. Department of Health and Human Services, National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009. [Cited: September 1, 2018]. Available from: [Link] 
  19. Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterology Res. 2018;11(4):264-273. [Crossref]  [PubMed]  [PMC] 
  20. Guo D, Li X, Xie A, et al. Differences in oncological outcomes and inflammatory biomarkers between right-sided and left-sided stage I-III colorectal adenocarcinoma. J Clin Lab Anal. 2020;34(4):e23132. [Crossref]  [PubMed]  [PMC] 
  21. Sakin A, Sahin S, Sakin A, et al. Assessment of pretreatment albumin-bilirubin grade in pancreatic cancer patients with liver metastasis. J BUON. 2020;25(4):1941-1946. [PubMed] 
  22. Kanda M, Tanaka C, Kobayashi D, et al. Preoperative albumin-bilirubin grade predicts recurrences after radical gastrectomy in patients with pT2-4 gastric cancer. World J Surg. 2018;42(3):773-781. [Crossref]  [PubMed] 
  23. Feng D, Wang M, Hu J, et al. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. Ann Transl Med. 2020;8(8):553. [Crossref]  [PubMed]  [PMC] 
  24. Beltrán L, González-Trejo S, Carmona-Herrera DD, et al. Prognostic factors and differences in survival of right and left colon carcinoma: A STROBE compliant retrospective cohort study. Arch Med Res. 2019;50(2):63-70. [Crossref]  [PubMed] 
  25. Yoon SE, Lee SJ, Lee J, et al. The impact of primary tumor sidedness on the effect of regorafenib in refractory metastatic colorectal cancer. J Cancer. 2019;10(7):1611-1615. [Crossref]  [PubMed]  [PMC] 
  26. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. [Crossref]  [PubMed] 
  27. Nogueira-Costa G, Fernandes I, Gameiro R, Gramaça J, Xavier AT, Pina I. Prognostic utility of neutrophil-to-lymphocyte ratio in patients with metastatic colorectal cancer treated using different modalities. Curr Oncol. 2020;27(5):237-243. [Crossref]  [PubMed]  [PMC] 
  28. Mazaki J, Katsumata K, Kasahara K, et al. Neutrophil-to-lymphocyte ratio is a prognostic factor for colon cancer: a propensity score analysis. BMC Cancer. 2020;20(1):922. [Crossref]  [PubMed]  [PMC] 
  29. Cha YJ, Park EJ, Baik SH, Lee KY, Kang J. Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy. Sci Rep. 2019;9(1):11617. [Crossref]  [PubMed]  [PMC] 
  30. Man Z, Pang Q, Zhou L, et al. Prognostic significance of preoperative prognostic nutritional index in hepatocellular carcinoma: a meta-analysis. HPB (Oxford). 2018;20(10):888-895. [Crossref]  [PubMed] 
  31. Wang Y, Battseren B, Yin W, et al. Predictive and prognostic value of prognostic nutritional index for locally advanced breast cancer. Gland Surg. 2019;8(6):618-626. [Crossref]  [PubMed]  [PMC] 
  32. Luvián-Morales J, González-Trejo S, Carrillo JF, et al. Association of the prognostic nutritional index and overall survival in patients with colorectal cancer: A STROBE compliant retrospective cohort study. Cancer Med. 2019;8(7):3379-3388. [Crossref]  [PubMed]  [PMC] 
  33. Bai X, Feng L. Correlation between Prognostic Nutritional Index, Glasgow Prognostic Score, Systemic Inflammatory Response, and TNM Staging in Colorectal Cancer Patients. Nutr Cancer. 2020;72(7):1170-1177. [Crossref]  [PubMed] 
  34. Wang Z, Fan Q, Wang M, Wang E, Li H, Liu L. Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma. Ann Transl Med. 2020;8(8):537. [Crossref]  [PubMed]  [PMC] 
  35. Zhang TN, Yin RH, Wang LW. The prognostic and predictive value of the albumin-bilirubin score in advanced pancreatic cancer. Medicine (Baltimore). 2020;99(28):e20654. [Crossref]  [PubMed]  [PMC] 
  36. Zhu C, Wang X, Chen S, et al. Efficacy of the preoperative albumin-bilirubin grade for predicting survival and outcomes of postoperative chemotherapy for advanced gastric cancer. Cancer Manag Res. 2020;12:11921-11932. [Crossref]  [PubMed]  [PMC] 
  37. Chojkier M. Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. J Clin Gastroenterol. 2005;39(4 Suppl 2):S143-146. [Crossref]  [PubMed] 
  38. Tanriverdi O. A discussion of serum albumin level in advanced-stage hepatocellular carcinoma: a medical oncologist's perspective. Med Oncol. 2014;31(11):282. [Crossref]  [PubMed]